201 related articles for article (PubMed ID: 38096800)
1. Genetically corrected RAG2-SCID human hematopoietic stem cells restore V(D)J-recombinase and rescue lymphoid deficiency.
Pavel-Dinu M; Gardner CL; Nakauchi Y; Kawai T; Delmonte OM; Palterer B; Bosticardo M; Pala F; Viel S; Malech HL; Ghanim HY; Bode NM; Kurgan GL; Detweiler AM; Vakulskas CA; Neff NF; Sheikali A; Menezes ST; Chrobok J; Hernández González EM; Majeti R; Notarangelo LD; Porteus MH
Blood Adv; 2024 Apr; 8(7):1820-1833. PubMed ID: 38096800
[TBL] [Abstract][Full Text] [Related]
2. Modeling altered T-cell development with induced pluripotent stem cells from patients with RAG1-dependent immune deficiencies.
Brauer PM; Pessach IM; Clarke E; Rowe JH; Ott de Bruin L; Lee YN; Dominguez-Brauer C; Comeau AM; Awong G; Felgentreff K; Zhang YH; Bredemeyer A; Al-Herz W; Du L; Ververs F; Kennedy M; Giliani S; Keller G; Sleckman BP; Schatz DG; Bushman FD; Notarangelo LD; Zúñiga-Pflücker JC
Blood; 2016 Aug; 128(6):783-93. PubMed ID: 27301863
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional clustering of human RAG2 gene mutations in severe combined immune deficiency.
Corneo B; Moshous D; Callebaut I; de Chasseval R; Fischer A; de Villartay JP
J Biol Chem; 2000 Apr; 275(17):12672-5. PubMed ID: 10777560
[TBL] [Abstract][Full Text] [Related]
4. Noncore RAG1 regions promote Vβ rearrangements and αβ T cell development by overcoming inherent inefficiency of Vβ recombination signal sequences.
Horowitz JE; Bassing CH
J Immunol; 2014 Feb; 192(4):1609-19. PubMed ID: 24415779
[TBL] [Abstract][Full Text] [Related]
5. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene.
van Til NP; de Boer H; Mashamba N; Wabik A; Huston M; Visser TP; Fontana E; Poliani PL; Cassani B; Zhang F; Thrasher AJ; Villa A; Wagemaker G
Mol Ther; 2012 Oct; 20(10):1968-80. PubMed ID: 22692499
[TBL] [Abstract][Full Text] [Related]
6. RAG1 and RAG2 in V(D)J recombination and transposition.
Fugmann SD
Immunol Res; 2001; 23(1):23-39. PubMed ID: 11417858
[TBL] [Abstract][Full Text] [Related]
7. RAG2 abolishes RAG1 aggregation to facilitate V(D)J recombination.
Gan T; Wang Y; Liu Y; Schatz DG; Hu J
Cell Rep; 2021 Oct; 37(2):109824. PubMed ID: 34644584
[TBL] [Abstract][Full Text] [Related]
8. Partial reconstitution of V(D)J rearrangement and lymphocyte development in RAG-deficient mice expressing inducible, tetracycline-regulated RAG transgenes.
Shockett PE; Zhou S; Hong X; Schatz DG
Mol Immunol; 2004 Jan; 40(11):813-29. PubMed ID: 14687938
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the V(D)J recombinase RAG1-RAG2.
Kim MS; Lapkouski M; Yang W; Gellert M
Nature; 2015 Feb; 518(7540):507-11. PubMed ID: 25707801
[TBL] [Abstract][Full Text] [Related]
10. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes.
IJspeert H; Driessen GJ; Moorhouse MJ; Hartwig NG; Wolska-Kusnierz B; Kalwak K; Pituch-Noworolska A; Kondratenko I; van Montfrans JM; Mejstrikova E; Lankester AC; Langerak AW; van Gent DC; Stubbs AP; van Dongen JJ; van der Burg M
J Allergy Clin Immunol; 2014 Apr; 133(4):1124-33. PubMed ID: 24418478
[TBL] [Abstract][Full Text] [Related]
11. The roles of the RAG1 and RAG2 "non-core" regions in V(D)J recombination and lymphocyte development.
Jones JM; Simkus C
Arch Immunol Ther Exp (Warsz); 2009; 57(2):105-16. PubMed ID: 19333736
[TBL] [Abstract][Full Text] [Related]
12. Human RAG mutations: biochemistry and clinical implications.
Notarangelo LD; Kim MS; Walter JE; Lee YN
Nat Rev Immunol; 2016 Apr; 16(4):234-46. PubMed ID: 26996199
[TBL] [Abstract][Full Text] [Related]
13. Omenn syndrome: a disorder of Rag1 and Rag2 genes.
Villa A; Santagata S; Bozzi F; Imberti L; Notarangelo LD
J Clin Immunol; 1999 Mar; 19(2):87-97. PubMed ID: 10226883
[TBL] [Abstract][Full Text] [Related]
14. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome.
van Til NP; Sarwari R; Visser TP; Hauer J; Lagresle-Peyrou C; van der Velden G; Malshetty V; Cortes P; Jollet A; Danos O; Cassani B; Zhang F; Thrasher AJ; Fontana E; Poliani PL; Cavazzana M; Verstegen MM; Villa A; Wagemaker G
J Allergy Clin Immunol; 2014 Apr; 133(4):1116-23. PubMed ID: 24332219
[TBL] [Abstract][Full Text] [Related]
15. Analysis of mutations from SCID and Omenn syndrome patients reveals the central role of the Rag2 PHD domain in regulating V(D)J recombination.
Couëdel C; Roman C; Jones A; Vezzoni P; Villa A; Cortes P
J Clin Invest; 2010 Apr; 120(4):1337-44. PubMed ID: 20234091
[TBL] [Abstract][Full Text] [Related]
16. Phenotypical heterogeneity in RAG-deficient patients from a highly consanguineous population.
Meshaal SS; El Hawary RE; Abd Elaziz DS; Eldash A; Alkady R; Lotfy S; Mauracher AA; Opitz L; Pachlopnik Schmid J; van der Burg M; Chou J; Galal NM; Boutros JA; Geha R; Elmarsafy AM
Clin Exp Immunol; 2019 Feb; 195(2):202-212. PubMed ID: 30307608
[TBL] [Abstract][Full Text] [Related]
17. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID.
Schuetz C; Neven B; Dvorak CC; Leroy S; Ege MJ; Pannicke U; Schwarz K; Schulz AS; Hoenig M; Sparber-Sauer M; Gatz SA; Denzer C; Blanche S; Moshous D; Picard C; Horn BN; de Villartay JP; Cavazzana M; Debatin KM; Friedrich W; Fischer A; Cowan MJ
Blood; 2014 Jan; 123(2):281-9. PubMed ID: 24144642
[TBL] [Abstract][Full Text] [Related]
18. The recombinase activating genes: architects of immune diversity during lymphocyte development.
Braams M; Pike-Overzet K; Staal FJT
Front Immunol; 2023; 14():1210818. PubMed ID: 37497222
[TBL] [Abstract][Full Text] [Related]
19. Amino acid residues in RAG1 responsible for the interaction with RAG2 during the V(D)J recombination process.
Ko JE; Kim CW; Kim DR
J Biol Chem; 2004 Feb; 279(9):7715-20. PubMed ID: 14670978
[TBL] [Abstract][Full Text] [Related]
20. Analysis of mutations and recombination activity in RAG-deficient patients.
Asai E; Wada T; Sakakibara Y; Toga A; Toma T; Shimizu T; Nampoothiri S; Imai K; Nonoyama S; Morio T; Muramatsu H; Kamachi Y; Ohara O; Yachie A
Clin Immunol; 2011 Feb; 138(2):172-7. PubMed ID: 21131235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
